Drug Profile
Research programme: autoimmune disorder therapeutics - Lycera/Merck & Co
Alternative Names: RORγt inhibitors - Lycera/Merck & CoLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Lycera
- Developer Lycera; Merck & Co
- Class Small molecules
- Mechanism of Action Retinoic acid receptor gamma antagonists; Th17 cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Autoimmune-disorders in USA (PO)